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Cyclin-dependent kinase inhibitors (CDKIs) are considered as novel anticancer agents because of their ability to induce growth arrest
or apoptosis in tumour cells. It has not yet been fully determined, however, which CDKI is the best candidate for the treatment of






KIP1), we compared the antitumour effect of CDKIs on malignant
glioma cell lines (A172, GB-1, T98G, U87-MG, U251-MG and U373-MG). p27
KIP1 showed higher ability to suppress the growth of all
tumour cells tested than other CDKIs. Interestingly, overexpression of p27
KIP1 induced autophagic cell death, but not apoptosis in
tumour cells. On the other hand, p27
KIP1 overexpression did not inhibit the viability of cultured astrocytes (RNB) nor induced
autophagy. Overall, our findings suggest that gene transfer of p27
KIP1 may be a promising approach for the therapy of malignant
gliomas.
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Cell cycle progression is controlled by cyclin-dependent kinases
(CDKs) that are activated by cyclin binding (Sherr, 1994; Morgan,
1995) and inhibited by CDK inhibitors (CDKIs) (Reed et al, 1994;
Sherr and Roberts, 1999). Two classes of CDKIs negatively regulate
the cell cycle (Sherr and Roberts, 1995; Harper and Elledge, 1996;
Xiong, 1996). One class, the inhibitor of CDK4 (INK4) family,





specifically binds CDK4 or CDK6 and inhibits cyclin D association
(Serrano et al, 1993; Guan et al, 1994; Hannon and Beach, 1994;
Hirai et al, 1995). The other class of CDKIs, the kinase inhibitor




inhibits cyclin-bound CDKs (Harper et al, 1993; Toyoshima and
Hunter, 1994; Lee et al, 1995).
Recent investigations show that exogenous induction of CDKIs
induces growth arrest or apoptosis in tumour cells, indicating the
potential use of CDKIs as a therapeutic tool (Guan et al, 1994;
Craig et al, 1997; Hiromura et al, 1999). However, it has not been
fully investigated which CDKI is the most useful for cancer therapy
and whether normal tissues are affected by CDKI expression. To
address these issues, in the present study, we compared the
antitumour effect of CDKIs on malignant glioma cell lines
and cultured astrocytes by using recombinant adenoviral vectors









Malignant glioma cells (A172, GB-1, T98G, U87-MG, U251-MG and
U373-MG) (Komata et al, 2000) and cultured astrocytes RNB
(Kondo et al, 1996) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, GIBCO BRL, Grand Island, NY, USA) supple-
mented with 10% fetal bovine serum (GIBCO BRL), 4mM
glutamine, 100Uml
 1 penicillin and 100mgml
 1 streptomycin.
Construction of recombinant adenoviral vectors
The recombinant AdMH4p16, AdMHp18, AdMH4p19, AdMH4p21






KIP1 were kindly supplied from Dr FL Graham
(McMaster University, Ontario, Canada). As described previously
(Schreiber et al, 1999), human p16 cDNA (pBluescriptSK-p16) was
obtained from Dr D Beach (Cold Spring Harbor, New York, USA).
pxep21, pAdcp17 and pAdcp19 were obtained from Dr T
Thompson (Baylor College of Medicine, Houston, TX, USA), and
pSCZhuwtp27 was a gift from Dr J Roberts (Fred Hutchison Cancer
Research Center, Seattle, WA, USA). AdBHGD1,3 containing El
and E3 deletions is a control recombinant adenovirus that
has identical backbone sequences to the adenoviral constructs
expressing CDKIs.
Adenoviral infection
The effect of CDKIs on cell viability was determined by using a
trypan blue dye exclusion assay as described previously (Komata Revised 20 January 2003; accepted 27 January 2003
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set al, 2000). To achieve the infectivity of 490%, A172, GB-1, U87-
MG, U251-MG, U373-MG and RNB cells were tested at a
multiplicity of infection (MOI) of 60PFUcell
 1. On the other
hand, T98G cells were infected with 180 MOI. The percentage of
cell viability was calculated from the mean cell viability of treated
cells divided by that of cells with control treatment. To detect the
expression of CDKI in infected cells, the immunoblotting assays
using anti-CDKI antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) were performed as described previously (Kondo et al,
1996).
Detection of apoptotic or autophagic cell death
To detect apoptosis, the terminal deoxynucleotidyl transferase
(Tdt)-mediated nick end labelling (TUNEL) analysis was performed
as described previously (Komata et al, 2000). To detect autophagic
changes in infected cells, cells were stained with acridine orange
(Poly-sciences, Warrington, PA, USA) as described previously
(Paglin et al, 2001). At 2 days after adenoviral infection, acridine
orange was added at a final concentration of 1mgml
 1 for 15min.
Microphotographs were obtained with a fluorescence microscope.
Statistical analysis
The data were expressed as means 7s.d. Statistical analysis was
performed by using Student’s t-test (two-tailed). The criterion for
statistical significance was taken as Po0.05.
RESULTS
Effect of CDKI overexpression on viability of malignant
glioma cells
To investigate the effect of CDKI on malignant glioma cell
lines, cell viability was determined 3 or 5 days after adenoviral







KIP1 for 3 days significantly
inhibited the cell viability compared to that with control vector
(Po0.002 to Po0.004). In U251-MG, U87-MG, A172 and GB-1,
similar antitumour effects were observed with each CDKI 3 days
after adenoviral infection (Po0.0002 to Po0.02). On the other
hand, the effect of AdMH4p18
INK4C or AdMH4p19
INK4D was not
significant for T98G cells (P¼0.17 or P¼0.71), although other
CDKIs were effective (Po0.0001 to Po0.03). Among the CDKIs
used in the present study, p27
KIP1 was more effective for tumour
cells than the other CDKIs. The number of viable cells of U373-MG
treated with AdMH4p27
KIP1 decreased below the initial cell
number (5000): 413871794 (day 3) or 255571042 (day 5). This
indicates that approximately half of p27
KIP1-infected U373-MG
cells underwent cell death by day 5. Additionally, cell number of
other tumour cell lines decreased by 30–60% from the initial cell
number like U373-MG cells 5 days after the treatment with
AdMH4p27
KIP1. These results indicate that 27
KIP1 has the highest
antitumour effect on all malignant glioma cells tested in the
present study.
Effect of p27
KIP1 in RNB cells
To investigate whether normal brain tissues are affected by p27
KIP1
expression, cultured rat astrocyte, RNB cells, were treated with
AdMH4p27
KIP1. As shown in Figure 2, the effect of p27
KIP1
overexpression was not significant for RNB cells, while the viability
of U373-MG cells decreased to 15% of the control (Po0.005). This
result suggested that p27
KIP1 -based therapy will be selective for
tumour cells.
Effect of p27
KIP1 on induction of apoptosis or autophagy
in U373-MG cells
To determine the type of cell death induced by AdMH4p27
KIP1,w e
first performed the TUNEL staining. The incidence of TUNEL-
positive cells in U373-MG cells treated with AdBHGD1,3 or
AdMH4p27
KIP1 for 3 or 5 days was less than 1%. Next, we
investigated the changes in the cellular acidic compartments to
detect the occurrence of autophagic cell death. Vital staining of
U373-MG cells with acridine orange revealed the appearance of
acidic vesicular organelles (AVO) 3 days after AdMH4p27
KIP1
infection (Figure 3). The staining of p27
KIP1-infected cells
clearly showed punctuate acidic vesicles that were diffusely
distributed in cytoplasm. In contrast, there was no change
of fluorescent signals in RNB cells treated with AdBHGD1,3 or
AdMH4p27
KIP1. These results indicated that the antitumour
effect of p27
KIP1 on malignant glioma cells was because of
autophagic cell death.
DISCUSSION
In the present study, we have demonstrated that p27
KIPl shows a
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Figure 1 Effect of adenovirus expressing CDKIs on cell viability of
malignant glioma cell lines. Tumour cells were seeded at 5 10
3
cellswell
 1 (0.1ml) in 96-well flat-bottomed plates and incubated over-
night at 371C. On the following day, U373-MG, U251-MG, U87-MG cells,
A172 cells, GB-1 and T98G cells were infected with AdBHGDl,3,
AdMH4pl6, AdMH4pl8, AdMH4pl9, AdMH4p21 or AdMH4p27 as
indicated (day 0). On day 3, the cell viability was determined using a
trypan blue dye exclusion assay. Values are given as the percentage of
viable cells of AdBHGDl ,3-infected cultures. Results shown are the
means7s.d. of three independent experiments. U373-MG, U251-MG,
U87-MG, A172 and GB-1 cells were infected at 60 MOI, while 180 MOI
was used for T98G cells.
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WAF1/CIP1) against six human mali-
gnant glioma cell lines. p27
KIPl-infected tumour cells under-
go autophagy, but not apoptotic cell death, while overexpression
of p27
KIP1 does not inhibit viability of cultured astrocytes. Our




KIP1 plays a central role in the negative control of cell growth.
p27
KIPl is generally expressed at high levels in cells arrested by
treatment with transforming growth factor-b, contact inhibition or
serum deprivation (Koff et al, 1993; Polyak et al, 1994). In contrast,
p27
KIP1 declines in the presence of mitogenic growth factor
signalling or interleukin-2 (Nourse et al, 1994; Cheng et al, 1998).
p27
KIP1-deficient mice develop a variety of abnormalities including
multiorgan hyperplasia and pituitary tumours (Nakayama et al,
1996). Furthermore, the higher the levels of p27
KIP1 expression, the
better the prognosis with regard to human malignant gliomas
(Alleyne et al, 1999), breast cancer (Porter et al, 1997) or lung
cancer (Esposito et al, 1997). Therefore, introduction of p27
KIP1
gene into tumour cells is expected to be a promising strategy to
inhibit their malignant cellular proliferation.
It has been controversial whether p27
KIP1 expression leads
tumour cells to growth arrest or cell death. Some groups
demonstrate the induction of growth arrest by p27
KIPl (Sherr and
Roberts, 1995; Craig et al, 1997). Others show that p27
KIP1
expression induces apoptosis in several cell lines (Katayose et al,
1997; Schreiber et al, 1999), while p27
KIPl protects cells from
apoptosis (Hiromura et al, 1999). In the present study, p27
KIP1
induced autophagic cell death, but not apoptosis in malignant
glioma cells. Recently, several groups have proposed two types of
programmed cell death (Schwartz et al, 1993; Bursch et al, 2000).
Type I programmed cell death, or apoptosis, is mediated by
caspases/bcl family, and has typical morphological and biochem-
ical characteristics such as chromatin condensation or nucleoso-
mal ladder formation. Since TUNEL-positive cells were not
detected in p27
KIP1-infected U373-MG cells in the present study,
it is unlikely that apoptosis is involved in the antitumour effect of
p27
KIP1 on malignant glioma cells. In contrast, type II programmed
cell death is marked morphologically by increased autophagy and
early destruction of the cytoplasm that occur either without
nuclear collapse or precedes it (Schwartz et al, 1993; Bursch et al,
2000). More recently, Paglin et al (2001) demonstrated that
formation of acidic vesicles was detected in radiation-induced
autophagy. Since the development of AVO was detected in p27
KIP1-
infected U373-MG cells, we suggest that the antitumour effect of
p27
KIP1 on malignant glioma cells is mainly because of induction
of type II programmed cell death, autophagy. Further study is
necessary to investigate the molecular mechanisms under-
lying p27
KIP1-induced autophagy in malignant glioma cells.
In summary, p27
KIP1 shows the most potent antitumour
effect against malignant glioma cells, while cultured astrocytes
are insensitive to p27
KIPl expression. The effect is because of auto-
phagic cell death as well as G0/G1 growth arrest. Therefore, we
expect that p27
KIP1-based therapy for malignant gliomas might be
a promising approach that is worth exploring further.
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Figure 2 Effect of AdMH4p27 on RNB cells. U373-MG or RNB cells
were seeded at 5 10
3 cellswell
 1 (0.1ml) in 96-well flat-bottomed plates
and incubated overnight at 371C. On the following day, cells were infected
with AdBHGDl,3 or AdMH4p27 at 60 MOI. On day 3, the cell viability was
determined using a trypan blue dye exclusion assay. Values are given as the
percentage of viable cells of AdBHGDl,3-infected cultures. Results shown
are the means7s.d. of three independent experiments.
RNB
U373-MG
Ad LacZ Ad p27
Figure 3 Effect of AdMH4p27 on induction of autophagy. At 72h after
the adenoviral infection with AdBHGDl,3 or AdMH4p27, U373-MG or
RNB cells were treated with 1mgml
 1 of acridine orange, and incubated at
371C for 15min. Viable cells were observed under the fluorescence
microscope. Results shown are representative of three independent
experiments.
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